Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03144206

Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study

A parallel-group randomized pilot trial at a single institution (Duke University) on the effect of postoperative hyperbaric oxygen therapy on wound healing in patients with soft tissue sarcoma undergoing surgical resection with neo-adjuvant radiation therapy.. Participants will be allocated to either the treatment group (HBOT) or control (standard of care) by computer-generated randomization, stratified by tumor size (≤10cm and >10cm). An unequal randomization of 2:1 will be utilized to provide experience prescribing HBOT to more patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Duke University

Durham, North Carolina, 273710, United States

About this study

Patients with a primary diagnosis of soft tissue sarcoma of the lower extremities undergoing treatment with neo-adjuvant radiation therapy and surgical resection will be screened for eligibility. All participants will receive pre-operative radiation treatment per standard of care and will undergo surgical excision as planned and performed by one of the surgical oncologists at our center. Participants randomized to the treatment group will be scheduled for 7-10 HBO treatments within 7-10 days of surgery. All participants will be scheduled for follow-up visits with their surgical oncologist at the following post-operative time points: 3, 6, 12, and 24-weeks (+/- 14 days). Follow up for the purposes of this study will continue up to 6 months from the time of surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females within the ages of 18-85
  • Diagnosis of soft tissue sarcoma that has been histologically confirmed by an approved reference pathologist
  • Sarcoma of lower extremity location
  • Treatment plan that includes neo-adjuvant radiation therapy followed by surgical resection
  • Expected primary wound closure performed at the time at surgery
  • Any disease stage
  • Any tumor grade
  • Any histologic subtype
  • First or recurrent presentations
  • No vascular invasion or resection/repair/reconstruction that results in decreased perfusion of the extremity
  • No history of radiation therapy to the tumor and/or surgical area prior to the current treatment being studied
  • Must be able to comply with follow up visits
  • Must be able to provide own consent

Exclusion criteria

  • Patients under the age of 18, or over the age of 85.
  • Treatment plan that doesn't include neo-adjuvant radiation and surgical excision
  • Sarcoma location other than lower extremity
  • History of radiation therapy to the tumor and/or surgical area prior to the current treatment being studied
  • High dose steroid therapy (defined as >5mg prednisone, or equivalent, daily)
  • Active treatment with chemotherapy
  • Inability of the patient to provide informed consent (i.e. dementia, cognitive impairment, non-English speakers)
  • Plan for post operative radiation therapy
  • Vascular invasion or resection/repair/reconstruction that results in decreased perfusion of the extremity
  • Vascular disease resulting in clinically apparent compromise in blood flow to the treatment extremity (i.e. peripheral vascular disease with diminished pulses, venous insufficiency with clinical evidence of vascular congestion)
  • Actively uncontrolled diabetes mellitus (documentation of history of diabetes mellitus with A1c>8)
  • Active deep vein thrombosis in the treatment extremity
  • Inability to comply with follow up visits
  • Pregnant females (women of childbearing potential must have a negative serum pregnancy test prior to enrollment)

Treatment and study plan

Hyperbaric oxygen

Drug

Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period

Primary outcomes

  1. Recruitment rate

    Time frame: Screening

    The proportion of eligible patients who enroll in this study, as indicated by the screening log.

  2. Hyperbaric Treatment Completion Rate

    Time frame: 24 weeks postoperatively

    The proportion of prescribed hyperbaric oxygen treatments that are completed, which will be recorded in the appointment log.

  3. Wound Assessment Form Completion Rate

    Time frame: 24 weeks postoperatively

    The number of completed Wound Assessment Forms per participant divided by the total number of follow-up visits per participant.

  4. Participant Assessment Form Completion Rate

    Time frame: 24 weeks postoperatively

    Number of completed Participant Assessment Forms per participant divided by the number of total follow-up visits per participant.

  5. patient reported study strengths and weaknesses

    Time frame: 24 weeks postoperatively

    The Patient Feedback Survey will be given to all participants at their final study-related visit in order to collect qualitative and quantitative data on patient reported study strengths and weaknesses.

  6. barriers to compliance with study procedures

    Time frame: 24 weeks postoperatively

    The Patient Feedback Survey will be given to all participants at their final study-related visit in order to collect qualitative and quantitative data on patient reported barriers to compliance with study procedures

Secondary outcomes

  1. Frequency of surgical site infections or periprosthetic infections

    Time frame: 24 weeks postoperatively

    the number of participants with ≥ 1 completed Wound Assessment Form documenting infection or treatment for infection around the wound area at any follow-up visit.

  2. frequency of wound complications that result in a secondary procedure

    Time frame: 24 weeks postoperatively

    the number of participants with ≥ 1 completed Wound Assessment Form that documents reoperation or any other invasive procedure after primary resection with any wound complication as the indication for the procedure.

  3. Wound Severity

    Time frame: 24 weeks postoperatively

    Variability in clinical evaluations of wound severity will be determined by the Bates-Jensen Wound Assessment score recorded in the Wound Assessment Form.

  4. Frequency of delayed wound healing

    Time frame: 24 weeks postoperatively

    The frequency of delayed wound healing will be determined by the number of participants with of ≥ 1 completed Wound Assessment Form documenting ≥ 1 clinical indication of a wound complication at any follow-up visit.

  5. Variability in Patient Reported Quality of Life

    Time frame: 24 weeks postoperatively

    Variability in patient reported outcome data pertaining to quality of life will be determined by the ESAS-SM score alone at baseline and by the ESAS-SM and WOUND-Q: Life Impact scores recorded in the Participant Assessment Form at all follow-up visits.

  6. Variability in Patient Reported Wound Assessments

    Time frame: 24 weeks postoperatively

    Variability in patient reported outcome data pertaining to wound assessments will be determined by the WOUND-Q: Wound Characterization score recorded in the Participant Assessment Form at all follow-up visits.

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Official study title

Randomized Pilot Study Evaluating Hyperbaric Oxygen Therapy Following Management of Soft Tissue Sarcoma With Neo-adjuvant Radiation and Surgical Resection

Important dates

Study start
2017
Primary completion
2026
Study completion
2026
First posted
May 8, 2017
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.